RAPT Therapeutics Inc
RAPT7.840USD
+6.810+661.17%
Cierre 06/17, 16:00（ET）Cotizaciones retrasadas 15 min
1.03BCap. mercado
PérdidaP/E TTM
Más Datos de RAPT Therapeutics Inc Compañía
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Información de la empresa
Símbolo de cotizaciónRAPT
Nombre de la empresaRAPT Therapeutics Inc
Fecha de salida a bolsaOct 31, 2019
Fundada en2015
Director ejecutivoDr. Brian Wong, M.D., Ph.D.
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
Dirección561 Eccles Ave
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono16504899000
Sitio Webhttps://rapt.com/
Símbolo de cotizaciónRAPT
Fecha de salida a bolsaOct 31, 2019
Fundada en2015
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Accionistas
Accionistas
Proporción
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
2.96%
Private Equity
2.84%
Hedge Fund
2.64%
Venture Capital
2.25%
Investment Advisor
1.68%
Research Firm
0.08%
Individual Investor
0.06%
Bank and Trust
0.01%
Family Office
0.01%
Other
87.49%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
301
145.36M
110.11%
+83.62M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
2022Q4
290
33.55M
97.48%
-1.41M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Medicxi Ventures (UK) LLP
22.35M
16.93%
+22.35M
--
Dec 31, 2024
OrbiMed Advisors, LLC
13.14M
9.95%
+13.14M
--
Dec 31, 2024
TCG Crossover Management, LLC
13.14M
9.95%
+13.14M
--
Dec 31, 2024
Foresite Capital Management, LLC
12.50M
9.47%
+12.50M
--
Dec 31, 2024
RTW Investments L.P.
11.76M
8.91%
+11.76M
--
Dec 31, 2024
BVF Partners L.P.
9.24M
7%
+9.24M
--
Dec 31, 2024
The Vanguard Group, Inc.
2.93M
2.22%
-8.95K
-0.30%
Jan 31, 2025
Redmile Group, LLC
6.48M
4.91%
+5.97M
+1.18K%
Dec 31, 2024
Deep Track Capital LP
6.01M
4.55%
+6.01M
--
Dec 31, 2024
Adar1 Capital Management LLC
1.17M
0.89%
+1.17M
+15.56K%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
Nuveen ESG Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Humankind US Stock ETF
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Ver más
Federated Hermes MDT Small Cap Core ETF
Proporción0.05%
iShares Micro-Cap ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0%
Nuveen ESG Small-Cap ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Humankind US Stock ETF
Proporción0%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
